ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 58 of 68
УЖМБС 2021, 6(5): 408–413

Effect of Resveratrol on Metabolic Syndrome

Markhon N. A., Baibakov V. М., Kosse V. A., Lyulko I. V., Titov G. I., Alekseenko Z. K., Topka E. G.

The purpose of the study is to analyze the sources of modern literature of domestic and foreign researchers on the prospects of resveratrol in the prevention and treatment of metabolic syndrome. Metabolic syndrome is a clinical manifestation characterized by many comorbidities, including hyperglycemia, abdominal obesity, hypertension, and dyslipidemia. All components of metabolic syndrome are involved in the induction of low-quality inflammation and oxidative stress, characteristic of this symptom complex. Metabolic syndrome is associated with an increased risk of cardiovascular disease and early mortality, which has a significant impact on health care costs. Finding an effective and alternative therapeutic strategy, which is natural and has no side effects, can be a useful tool in the fight against metabolic syndrome. This review focuses on the potential beneficial effects of a polyphenolic natural compound – resveratrol – on various molecular targets with programming for the development of disorders associated with metabolic syndrome and its comorbidities. A number of data on the effects of resveratrol on body weight, insulin sensitivity, glucose tolerance, lipid profile, blood pressure, oxidative stress indicate that this compound has a wide range of beneficial effects on human health, and also has a beneficial effect on metabolic syndrome. A numerous data on the improvement of homeostasis, glucose, lipids, fat reduction, blood pressure, oxidative stress may demonstrate how resveratrol may be useful in the prevention and treatment of metabolic syndrome and related disorders due to its anti-inflammatory, antiplatelet and antioxidant properties. Resveratrol can be used either early as a reprogramming agent or later as a part of the treatment of metabolic syndrome. A few of the main molecular mechanisms underlying the beneficial effects of resveratrol on metabolic syndrome are given in the article. Conclusion. Presented review of literature outlined the potential of resveratrol as supplementary or alternative medicine. Thus, resveratrol could be a useful regimen for the prevention and treatment of metabolic syndrome and its related conditions. The article considers some molecular level targets for resveratrol in terms of its effect on the metabolic syndrome, such as adenosine monophosphate-activated protein kinase, SIRT1 protein, the main switch of the cellular defense system (Nrf2), nuclear factor-kappa B, estrogen receptor and the like

Keywords: resveratrol, phytoalexin, metabolic syndrome

Full text: PDF (Ukr) 321K

  1. Tain Yl, Hsu CN. Developmental Programming of the Metabolic Syndrome: Can We Reprogram with Resveratrol? Int J Mol Sci. 2018; 19(2584): 1-12.
  2. Ambrosova TM. Terapevtycheskaya korrektsyya aterogennoy dyslypydemyy pry metabolycheskom syndrome [Therapeutic correction of atherogenous dlypidemia in metabolic syndrome]. Mezhdunar Med Zh. 2013; 3: 50-5. [Russian]
  3. Shin JA, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig. 2013 Jul 8; 4(4): 334-43.
  4. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017 Aug; 11(8): 215-25.
  5. Taghipour YS, Hajialyani M, Naseri R, Hesari M, Stefanucci A, Mollica A, et al. Nanoformulations of natural products for management of metabolic syndrome. Int J Nanomedicine. 2019 Jul; 14: 5303-21.
  6. Kopchak OO. Metabolichnyy syndrom ta yogo vklad u rozvytok sudynnykh kognityvnykh porushen [Metabolic syndrome and its contribution to the development of vascular cognitive violations]. Ukr Med Chasopys. 2014; 2(100): 178-82. [Ukrainian]
  7. Prokudyna ES, Maslov LM, Ivanov VV, Bespalova YD, Pysmennyy DS, Voronkov NS. Rol aktyvnykh form kysloroda v patogeneze dysfunktsyy adypotsytov pry metabolycheskom syndrome: perspektyvy farmakologycheskoy korrektsyy [The role of active forms of oxygen in the pathogenesis of adipocyte dysfunction during metabolic syndrome: Perspectives of pharmacological correction]. Aktualnye voprosy byokhymyy - Vestnyk RAMN. 2017; 72(1): 11-16. [Russian].
  8. Thaman R, Arora G. Metabolic Syndrome: Definition and Pathophysiology - the discussion goes on! J Phys Pharm Adv. 2013; 3(3): 48-56.
  9. DeBoer MD. Assessing and Managing the Metabolic Syndrome in Children and Adolescents. Nutrients. 2019 Aug; 11(8): 1-12.
  10. Weiss R, Bremmer AA, Lustig RH. What is metabolic syndrome, and why are children getting it? Ann NY Acad Sci. 2013 Apr; 1281: 123-40.
  11. Lytvynova LS, Kyryenkova EV, Mazunyn YO, Vasylenko MA, Fattakhov NS. Patogenez ynsulynorezystentnosty pry metabolycheskom ozhyrenyy [Pathogenesis of insulin resistance in metabolic obesity]. Byomed khymyya. 2015; 61(1): 70-82. [Russian].
  12. Roytberg GE, Dorosh ZhV, Sharkhun OO, Ushakova TY, Trubyno EA. Vozmozhnosty prymenenyya novogo metabolycheskogo yndeksa pry otsenke ynsulynorezystentnosty v klynycheskoy praktyke [The possibility of applying a new metabolic index when assessing insulin resistance in clinical practice]. Ratsyonalnaya farmakoterapyya v kardyologyy. 2014; 10(3): 264-74. [Russian].
  13. Tain YL, Joles JA. Reprogramming: A preventive strategy in hypertension focusing on the kidney. Int J Mol Sci. 2015; 17: 1-15.
  14. Tain YL, Chan SHH, Chan JYH. Biochemical basis for pharmacological intervention as a reprogramming strategy against hypertension and kidney disease of developmental origin. Biochem Pharmacol. 2018; 153: 82-90.
  15. Sokolova LK, Pushkarov VM, Tronko MD. Efekty resveratrolu v normi ta za riznykh patologiy [The effects of resveratrol normally and with different pathologies]. Endokrynologiya. 2020; 25(1): 76-88. [Ukrainian].
  16. Diaz-Gerevini GT, Repossi G, Dain A, Tarres MC, Das UN, Eynard AR. Beneficial action of resveratrol: How and why? Nutrition. 2016; 32: 174-178.
  17. Bonnefont-Rousselot D. Resveratrol and Cardiovascular Diseases. Nutrients. 2016; 8: 1-24.
  18. Uspenskaya YB. Klynycheskye effekty resveratrola (obzor lyteratury) [Clinical effects of resveratrol (literature review)]. Gynekologyya. 2014; 16(5): 96-102. [Russian].
  19. Chaplin A, Carpéné C, Mercader J. Resveratrol, Metabolic Syndrome, and Gut Microbiota. Nutrients. 2018; 10(1651): 1-29.
  20. Hou CY, Tain YL, Yu HR, Huang LT. The Effects of Resveratrol in the Treatment of Metabolic Syndrome. Int J Mol Sci. 2019; 20(535): 1-15.
  21. Kulkarni, SS, Canto C. The molecular targets of resveratrol. Biochim Biophys Acta. 2015; 1852: 1114-1123.
  22. Umezawa S, Higurashi T, Nakajima A. AMPK: Therapeutic Target for Diabetes and Cancer Prevention. Curr Pharm Des. 2017; 23: 3629-3644.
  23. Zordoky BNM, Robertson IM, Dyck JRB. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta Affiliations expand. 2015 Jun; 1852(6): 1155-77.
  24. Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D, et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta. 2013 Oct; 1832(10): 1723-33.
  25. Tain YL, Hsu CN. AMP-Activated Protein Kinase as a Reprogramming Strategy for Hypertension and Kidney Disease of Developmental Origin. Int J Mol Sci. 2018 Jun 12; 19(6): 1-13.
  26. Kane AE, Sinclair DA. Sirtuins and NAD + in the Development and Treatment of Metabolic and Cardiovascular Diseases. Circ Res. 2018 Sep; 123(7): 868-85.
  27. Elibol B, Kilic U. High Levels of SIRT1 Expression as a Protective Mechanism Against Disease-Related Conditions. Front Endocrinol. 2018 Oct; 9(614): 1-7.
  28. Mendez-del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Lizarraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014; 12(10): 497-501.
  29. Kim EN, Kim MY, Lim JH, Kim Y, Shin SJ, Park CW, et al. The protective effect of resveratrol on vascular aging by modulation of the renin-angiotensin system. Atherosclerosis. 2018; 270: 123-31.
  30. Menikdwela KR, Ramalingam L, Rasha F, Wang Shu, Dufour JM, Kalupahana NS, et al. Autophagy in metabolic syndrome: breaking the wheel by targeting the renin-angiotensin system. Cell Death Dis. 2020 Feb; 11(2): 1-17.
  31. Jahandibeh F, Wu J. Perspectives on the Potential Benefits of Antihypertensive Peptides towards Metabolic Syndrome. Int J Mol Sci. 2020 Mar 22; 21(6): 1-23.
  32. Kong D, Yari Y, He XY, Yang H, Liang BY, Wang J. Effects of Resveratrol on the Mechanisms of Antioxidants and Estrogen in Alzheimer's Disease. Biomed Res Int. 2019 Mar 20; 2019: 1-8.
  33. Koeners MP, Wesseling S, Sánchez M, Braam B, Joles JA. Perinatal inhibition of NF-kappa B has long-term antihypertensive and renoprotective effects in fawn-hooded hypertensive rats. Am J Hypertens. 2016; 29: 123-131.